Mobile Tool to Help Patients With Bladder Cancer Track Quality of Life
Asks adults with urothelial carcinoma which contents they find useful in a web app.
Key facts
- Who runs it
- IRCCS San Raffaele
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 30 Jun 2025
- Planned end
- 31 Oct 2025
- Type of study
- Observational
- Record updated
- 21 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with urothelial carcinoma who are about to start, or have started, systemic treatment. They answer questionnaires about what a future web app should include.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Urothelial carcinoma confirmed by tissue examination (histological diagnosis).
- Earlier treatment
- Candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or target therapy. People who have already started treatment can also join.
Main reasons for not taking part
- Does not have a mobile device (for example a smartphone or personal computer)
- Does not understand or speak Italian
- Cannot or does not want to sign the informed consent
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- histological diagnosis of urothelial carcinoma
- ≥ 18 years old,
- candidate for systemic treatment with chemotherapy, immune-checkpoint inhibitors, antibody-drug conjugates, or target therapy (patients can be enrolled also if the treatment has started),
- possession of a mobile device (e.g., smartphone or personal computer) with the physical and psychological ability to use mobile devices,
- understanding and speaking the Italian language,
- ability to sign an informed consent
Who cannot take part
- not possession of a mobile device,
- unwillingness to give informed consent
Where in Italy
- IRCCS San RaffaeleMilan, ItalyContact: Brigida A Maiorano, MD, PhDTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to select contents and tools for the future development of a web app aiming to support patients' navigation for empowering decision-making through a higher awareness of urothelial carcinoma and its treatments, improving also educational aspects.
Read full original descriptionShow less
The main question it aims to answer is:
What are the contents that patients diagnosed with urothelial carcinoma find useful to include in a web app to streamline their quality of life assessment and monitoring?
Participants candidate for systemic treatments, or already under treatment, will answer questionnaires about the tools to include in a web app designed for urothelial carcinoma.
The group in the trial
- Patients with urothelial carcinoma candidate to receive systemic therapy, having a mobile device
Patients will receive a researcher-made questionnaire to gather the demographic and clinical characteristics of the respondents (age, sex, educational level, employment status, type of treatment for UC, physical activity, familiarity and caregiver status, interest, and comfortability with mobile devices and apps). Paper questionnaires containing the main contents to be included in the future development of the 'Urolife' web-app will be presented. Four categories of educational and self-management contents will be proposed: 1. Quality of life questionnaires; 2. Self-education on symptoms and AEs tool; 3. Links to verified patients' forums and support organizations for UC; 4. Educational videos and podcasts. Patients will have the opportunity to propose other useful tools. Each tool will be rated by the patients. User needs will be elicited through co-creation sessions held with the Design Thinking method.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- 'UROLIFE': a Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
- Plain-language title
- Mobile Tool to Help Patients With Bladder Cancer Track Quality of LifeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 May 2025